• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13D/A filed by Third Harmonic Bio Inc.

    11/5/24 6:26:23 PM ET
    $THRD
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $THRD alert in real time by email
    SC 13D/A 1 tm2427598d1_sc13da.htm SC 13D/A

     

     

    UNITED STATES 

    SECURITIES AND EXCHANGE COMMISSION 

    Washington, D.C. 20549

     

    SCHEDULE 13D/A

     

    Under the Securities Exchange Act of 1934 

    (Amendment No. 1)*

     

    THIRD HARMONIC BIO, INC. 

    (Name of Issuer)

     

    Common Stock, $0.0001 par value per share 

    (Title of Class of Securities)

     

    88427A 10 7 

    (CUSIP Number)

     

    Atlas Venture 

    Attention: Ommer Chohan, Chief Financial Officer 

    300 Technology Square, 8th Floor 

    Cambridge, MA 02139 USA 

    (857) 201-2700 

    (Name, Address and Telephone Number of Person Authorized to 

    Receive Notices and Communications)

     

    November 1, 2024 

    (Date of Event which Requires Filing of this Statement)

     

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.¨

     

    Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See §240.13d-7 for other parties to whom copies are to be sent.

     

    * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

     

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

    CUSIP 88427A 10 7 Page 2 of 10

     

    1  

    NAMES OF REPORTING PERSONS:

    ATLAS VENTURE FUND XI, L.P. 

    2  

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS):

    (a) ¨ (b) x

    3   SEC USE ONLY:
    4  

    SOURCE OF FUNDS (SEE INSTRUCTIONS):

    WC 

    5  

    CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e):

    ¨ 

    6  

    CITIZENSHIP OR PLACE OF ORGANIZATION:

    Delaware 

    NUMBER
    OF SHARES
    BENEFICIALLY
    OWNED
    BY EACH
    REPORTING
    PERSON WITH
      7  

    SOLE VOTING POWER:

    0 

      8  

    SHARED VOTING POWER:

    9,798,0751

      9  

    SOLE DISPOSITIVE POWER:

    0 

      10  

    SHARED DISPOSITIVE POWER:

    9,798,0751

    11  

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON:

    9,798,0751

    12  

    CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS):

    ¨ 

    13  

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11):

    23.8%2

    14  

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS):

    PN 

               

     

      1 As described in Item 5 below, Atlas Venture Fund XI, L.P., a Delaware limited partnership (“Atlas XI”) directly holds 9,798,075 shares of the Issuer’s Common Stock. Atlas Venture Associates XI, L.P., a Delaware limited partnership (“AVA XI LP”) and Atlas Venture Associates XI, LLC, a Delaware limited liability company (“AVA XI LLC” and together with Atlas XI and AVA XI LP, the “Fund XI Reporting Persons”) beneficially own the shares of the Issuer’s Common Stock held by Atlas XI.  AVA XI LP is the general partner of Atlas XI and AVA XI LLC is the general partner of AVA XI LP. Each of AVA XI LP and AVA XI LLC has voting and dispositive power over the shares held by Atlas XI.

     

      2 This percentage is calculated based upon 41,097,512 outstanding shares of Common Stock of the Issuer, as reported in the Issuer’s Form 10-Q, filed with the Securities and Exchange Commission on August 8, 2024.

     

     

     

     

    CUSIP 88427A 10 7 Page 3 of 10

     

    1  

    NAMES OF REPORTING PERSONS:

    ATLAS VENTURE ASSOCIATES XI, L.P. 

    2  

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS):

    (a) ¨ (b) x

    3   SEC USE ONLY:
    4  

    SOURCE OF FUNDS (SEE INSTRUCTIONS):

    AF 

    5  

    CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e):

    ¨ 

    6  

    CITIZENSHIP OR PLACE OF ORGANIZATION:

    Delaware 

    NUMBER
    OF SHARES
    BENEFICIALLY
    OWNED
    BY EACH
    REPORTING
    PERSON WITH
      7  

    SOLE VOTING POWER:

    0 

      8  

    SHARED VOTING POWER:

    9,808,1901

      9  

    SOLE DISPOSITIVE POWER:

    0 

      10  

    SHARED DISPOSITIVE POWER:

    9,808,1901

    11  

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON:

    9,808,1901

    12  

    CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS):

    ¨ 

    13  

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11):

    23.9%2

    14  

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS):

    PN 

               

     

      1 As described in Item 5 below, Atlas XI and AVA XI LP hold 9,798,075 and 10,115 shares of the Issuer’s Common Stock, respectively. AVA XI LP is the general partner of Atlas XI and AVA XI LLC is the general partner of AVA XI LP. Each of AVA XI LP and AVA XI LLC has voting and dispositive power over the shares held by Atlas XI and AVA XI LLC has voting and dispositive power over the shares held by AVA XI LP.

     

      2 This percentage is calculated based upon 41,097,512 outstanding shares of Common Stock of the Issuer, as reported in the Issuer’s Form 10-Q, filed with the Securities and Exchange Commission on August 8, 2024.

     

     

     

     

    CUSIP 88427A 10 7 Page 4 of 10

     

    1  

    NAMES OF REPORTING PERSONS:

    Atlas Venture Associates XI, LLC  

    2  

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS):

    (a) ¨ (b) x

    3   SEC USE ONLY:
    4  

    SOURCE OF FUNDS (SEE INSTRUCTIONS):

    AF 

    5  

    CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e):

    ¨ 

    6  

    CITIZENSHIP OR PLACE OF ORGANIZATION:

    Delaware 

    NUMBER
    OF SHARES
    BENEFICIALLY
    OWNED
    BY EACH
    REPORTING
    PERSON WITH
      7  

    SOLE VOTING POWER:

    0 

      8  

    SHARED VOTING POWER:

    9,808,1901

      9  

    SOLE DISPOSITIVE POWER:

    0 

      10  

    SHARED DISPOSITIVE POWER:

    9,808,1901

    11  

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON:

    9,808,1901

    12  

    CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS):

    ¨ 

    13  

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11):

    23.9%2

    14  

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS):

    OO 

               

     

      1 As described in Item 5 below, Atlas XI and AVA XI LP hold 9,798,075 and 10,115 shares of the Issuer’s Common Stock, respectively. AVA XI LP is the general partner of Atlas XI and AVA XI LLC is the general partner of AVA XI LP. Each of AVA XI LP and AVA XI LLC has voting and dispositive power over the shares held by Atlas XI and AVA XI LLC has voting and dispositive power over the shares held by AVA XI LP.

     

      2 This percentage is calculated based upon 41,097,512 outstanding shares of Common Stock of the Issuer, as reported in the Issuer’s Form 10-Q, filed with the Securities and Exchange Commission on August 8, 2024.

     

     

     

     

    CUSIP 88427A 10 7 Page 5 of 10

     

    1  

    NAMES OF REPORTING PERSONS:

    ATLAS VENTURE OPPORTUNITY FUND I, L.P.  

    2  

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS):

    (a) ¨ (b) x

    3   SEC USE ONLY:
    4  

    SOURCE OF FUNDS (SEE INSTRUCTIONS):

    WC 

    5  

    CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e):

    ¨ 

    6  

    CITIZENSHIP OR PLACE OF ORGANIZATION:

    Delaware 

    NUMBER
    OF SHARES
    BENEFICIALLY
    OWNED
    BY EACH
    REPORTING
    PERSON WITH
      7  

    SOLE VOTING POWER:

    0 

      8  

    SHARED VOTING POWER:

    594,0961

      9  

    SOLE DISPOSITIVE POWER:

    0 

      10  

    SHARED DISPOSITIVE POWER:

    594,0961

    11  

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON:

    594,0961

    12  

    CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS):

    ¨ 

    13  

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11):

    1.4%2

    14  

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS):

    PN 

               

     

      1 As described in Item 5 below, Atlas Venture Opportunity Fund I, L.P., a Delaware limited partnership (“AVOF”), Atlas Venture Associates Opportunity I, L.P., a Delaware limited partnership (“AVAO LP”) and Atlas Venture Associates Opportunity I, LLC, a Delaware limited liability company (“AVAO LLC” and together with AVOF and AVAO LP, the “Opportunity Fund Reporting Persons”) beneficially own 594,096 shares of the Issuer’s Common Stock. All of these shares are held by AVOF. AVAO LP is the general partner of AVOF and AVAO LLC is the general partner of AVAO LP. Each of AVAO LP and AVAO LLC has voting and dispositive power over the shares held by AVOF. As such, each of the Opportunity Fund Reporting Persons share voting and dispositive power with respect to the shares held by AVOF.

     

      2 This percentage is calculated based upon 41,097,512 outstanding shares of Common Stock of the Issuer, as reported in the Issuer’s Form 10-Q, filed with the Securities and Exchange Commission on August 8, 2024.

     

     

     

     

    CUSIP 88427A 10 7 Page 6 of 10

     

    1  

    NAMES OF REPORTING PERSONS:

    Atlas Venture Associates Opportunity I, L.P.  

    2  

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS):

    (a) ¨ (b) x 

    3   SEC USE ONLY:
    4  

    SOURCE OF FUNDS (SEE INSTRUCTIONS):

    AF 

    5  

    CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e):

    ¨ 

    6  

    CITIZENSHIP OR PLACE OF ORGANIZATION:

    Delaware 

    NUMBER
    OF SHARES
    BENEFICIALLY
    OWNED
    BY EACH
    REPORTING
    PERSON WITH
      7  

    SOLE VOTING POWER:

    0 

      8  

    SHARED VOTING POWER:

    594,0961

      9  

    SOLE DISPOSITIVE POWER:

    0 

      10  

    SHARED DISPOSITIVE POWER:

    594,0961

    11  

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON:

    594,0961

    12  

    CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS):

    ¨ 

    13  

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11):

    1.4%2

    14  

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS):

    PN 

               

     

      1 As described in Item 5 below, AVOF, AVAO LP and AVAO LLC beneficially own 594,096 shares of the Issuer’s Common Stock. All of these shares are held by AVOF. AVAO LP is the general partner of AVOF and AVAO LLC is the general partner of AVAO LP. Each of AVAO LP and AVAO LLC has voting and dispositive power over the shares held by AVOF. As such, each of the Opportunity Fund Reporting Persons share voting and dispositive power with respect to the shares held by AVOF.

     

      2 This percentage is calculated based upon 41,097,512 outstanding shares of Common Stock of the Issuer, as reported in the Issuer’s Form 10-Q, filed with the Securities and Exchange Commission on August 8, 2024.

     

     

     

     

    CUSIP 88427A 10 7 Page 7 of 10

     

    1  

    NAMES OF REPORTING PERSONS:

    Atlas Venture Associates Opportunity I, LLC 

    2  

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS):

    (a) ¨ (b) x 

    3   SEC USE ONLY:
    4  

    SOURCE OF FUNDS (SEE INSTRUCTIONS):

    AF 

    5  

    CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e):

    ¨ 

    6  

    CITIZENSHIP OR PLACE OF ORGANIZATION:

    Delaware 

    NUMBER
    OF SHARES
    BENEFICIALLY
    OWNED
    BY EACH
    REPORTING
    PERSON WITH
      7  

    SOLE VOTING POWER:

    0 

      8  

    SHARED VOTING POWER:

    594,0961

      9  

    SOLE DISPOSITIVE POWER:

    0 

      10  

    SHARED DISPOSITIVE POWER:

    594,0961

    11  

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON:

    594,0961

    12  

    CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS):

    ¨ 

    13  

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11):

    1.4%2

    14  

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS):

    OO 

               

     

      1 As described in Item 5 below, AVOF, AVAO LP and AVAO LLC beneficially own 594,096 shares of the Issuer’s Common Stock. All of these shares are held by AVOF. AVAO LP is the general partner of AVOF and AVAO LLC is the general partner of AVAO LP. Each of AVAO LP and AVAO LLC has voting and dispositive power over the shares held by AVOF. As such, each of the Opportunity Fund Reporting Persons share voting and dispositive power with respect to the shares held by AVOF.

     

      2 This percentage is calculated based upon 41,097,512 outstanding shares of Common Stock of the Issuer, as reported in the Issuer’s Form 10-Q, filed with the Securities and Exchange Commission on August 8, 2024.

     

     

     

     

    CUSIP 88427A 10 7   Page 8 of 10

     

    INTRODUCTION

     

    This Amendment No. 1 to Schedule 13D (“Amendment No. 1”) is being filed as an amendment to the statement on Schedule 13D relating to common stock, par value $0.0001 per share (the “Common Stock”) of Third Harmonic Bio, Inc. a Delaware corporation (the “Issuer” or “Third Harmonic”), as filed with the Securities and Exchange Commission (the “SEC”) on September 29, 2022 (the “Initial Schedule 13D”). All capitalized terms not otherwise defined herein shall have the meanings ascribed to the terms in the Initial Schedule 13D. This Amendment No. 1 is being filed to report the distribution of shares by Atlas XI, as described herein.

     

    The Initial Schedule 13D is hereby amended and supplemented as follows and, except as expressly amended below, the Prior Schedule 13D remains in full force and effect.

     

    ITEM 1. SECURITY AND ISSUER

     

    The class of equity securities to which this Schedule 13D relates is common stock, par value $0.0001 per share (the “Common Stock”) of Third Harmonic Bio, Inc., a Delaware corporation (the “Issuer” or “Third Harmonic Bio”). The principal executive offices of the Issuer are located at 1700 Montgomery Street, Suite  210, San Francisco, California 94111.

     

     

     

     

     CUSIP 88427A 10 7 Page 9 of 10

     

    ITEM 5. INTEREST IN SECURITIES OF THE ISSUER

     

      (a)(b) As of the date hereof, Atlas XI is the record owner of 9,798,075 shares of Common Stock. AVA XI LP is the general partner of Atlas XI and AVA XI LLC is the general partner of AVA XI LP. Each of Atlas XI, AVA XI LP and AVA XI LLC has shared voting and dispositive power over the shares held by Atlas XI. As such, each of Atlas XI, AVA XI LP and AVA XI LLC may be deemed to beneficially own the shares held by Atlas XI.

     

    As of the date hereof, AVA XI LP is the record owner of 10,115 shares of Common Stock. AVA XI LLC is the general partner of AVA XI LP. Each of AVA XI LP and AVA XI LLC has shared voting and dispositive power over the shares held by AVA XI LP. As such, each of AVA XI LP and AVA XI LLC may be deemed to beneficially own the shares held by AVA XI LP.

     

    As of the date hereof, AVOF is the record owner of 594,096 shares of Common Stock. AVAO LP is the general partner of AVOF and AVAO LLC is the general partner of AVAO LP. Each of AVOF, AVAO LP and AVAO LLC has shared voting and dispositive power over the shares held by AVOF. As such, each of AVOF, AVAO LP and AVAO LLC may be deemed to beneficially own the shares held by AVOF.

     

    Each of the Fund XI Reporting Persons and Opportunity Fund Reporting Persons may be deemed to beneficially own 23.9% and 1.4%, respectively, of the Issuer’s outstanding Common Stock, which percentages are calculated based upon 41,097,512 outstanding shares of Common Stock of the Issuer, as reported in the Issuer’s Form 10-Q, filed with the Securities and Exchange Commission on August 8, 2024.

     

    Collectively, the Reporting Persons beneficially own an aggregate of 10,402,286 shares of Common Stock, which represents 25.3% of the Issuer's outstanding Common Stock. The Fund XI Reporting Persons and the Opportunity Fund Reporting Persons are under common control and as a result, the Reporting Persons may be deemed to be members of a group. However, the Reporting Persons disclaim such group membership, and this Schedule 13D shall not be deemed an admission that the Reporting Persons are members of a group for purposes of Section 13 or for any other purposes.

     

      (c) On November 1, 2024, Atlas XI distributed 515,688 shares of the Issuer’s Common Stock to its general partner and limited partners without additional consideration pursuant to a distribution plan adopted in accordance with Rule 10b5-1.

     

      (d) No other person is known by the Reporting Persons to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the shares of Common Stock beneficially owned by the Reporting Persons.

     

    (e) Not applicable.

     

     

     

     

    CUSIP 88427A 10 7 Page 10 of 10

     

    SIGNATURES

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: November 5, 2024

     

    ATLAS VENTURE FUND XI, L.P.
     
    By: Atlas Venture Associates XI, L.P., its general partner
    By: Atlas Venture Associates XI, LLC, its general partner
         
    By: /s/ Ommer Chohan                                                       
    Name: Ommer Chohan  
    Title: Chief Financial Officer  
         
         
    ATLAS VENTURE ASSOCIATES XI, L.P.
         
    By: Atlas Venture Associates XI, LLC, its general partner
         
    By: /s/ Ommer Chohan  
    Name: Ommer Chohan  
    Title: Chief Financial Officer  
         
         
    ATLAS VENTURE ASSOCIATES XI, LLC
         
    By: /s/ Ommer Chohan  
    Name: Ommer Chohan  
    Title: Chief Financial Officer  
         
    ATLAS VENTURE OPPORTUNITY FUND I, L.P.
         
    By: Atlas Venture Associates Opportunity I, L.P., its general partner
    By: Atlas Venture Associates Opportunity I, LLC, its general partner

     

    By: /s/ Ommer Chohan                                                            
    Name: Ommer Chohan  
    Title: Chief Financial Officer  
         
    ATLAS VENTURE ASSOCIATES OPPORTUNITY I, L.P.
         
    By: Atlas Venture Associates Opportunity I, LLC, its general partner
         
    By: /s/ Ommer Chohan  
    Name: Ommer Chohan  
    Title: Chief Financial Officer  
         
    ATLAS VENTURE ASSOCIATES OPPORTUNITY I, LLC
         
    By: /s/ Ommer Chohan  
    Name: Ommer Chohan  
    Title: Chief Financial Officer  

     

     

     

    Get the next $THRD alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $THRD

    DatePrice TargetRatingAnalyst
    3/28/2025$23.00 → $5.00Buy → Hold
    Stifel
    2/12/2025$20.00 → $5.00Overweight → Equal-Weight
    Morgan Stanley
    2/11/2025Outperform → Mkt Perform
    Raymond James
    8/9/2024$12.00 → $20.00Equal-Weight → Overweight
    Morgan Stanley
    6/18/2024$23.00Buy
    Stifel
    6/7/2024$18.00Outperform
    Raymond James
    More analyst ratings

    $THRD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Chief Financial & Bus. Officer Murphy Christopher M.

      4 - Third Harmonic Bio, Inc. (0001923840) (Issuer)

      3/5/25 4:01:29 PM ET
      $THRD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Chief Financial & Bus. Officer Murphy Christopher M.

      4 - Third Harmonic Bio, Inc. (0001923840) (Issuer)

      1/17/25 6:10:34 PM ET
      $THRD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Chief Operating Officer Dittman Jennifer

      4 - Third Harmonic Bio, Inc. (0001923840) (Issuer)

      1/17/25 6:09:33 PM ET
      $THRD
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $THRD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Third Harmonic Bio Inc.

      SC 13G/A - Third Harmonic Bio, Inc. (0001923840) (Subject)

      11/14/24 5:46:12 PM ET
      $THRD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Third Harmonic Bio Inc.

      SC 13G - Third Harmonic Bio, Inc. (0001923840) (Subject)

      11/14/24 1:28:35 PM ET
      $THRD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Third Harmonic Bio Inc.

      SC 13D/A - Third Harmonic Bio, Inc. (0001923840) (Subject)

      11/12/24 6:04:36 PM ET
      $THRD
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $THRD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Third Harmonic Bio downgraded by Stifel with a new price target

      Stifel downgraded Third Harmonic Bio from Buy to Hold and set a new price target of $5.00 from $23.00 previously

      3/28/25 8:16:37 AM ET
      $THRD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Third Harmonic Bio downgraded by Morgan Stanley with a new price target

      Morgan Stanley downgraded Third Harmonic Bio from Overweight to Equal-Weight and set a new price target of $5.00 from $20.00 previously

      2/12/25 7:12:21 AM ET
      $THRD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Third Harmonic Bio downgraded by Raymond James

      Raymond James downgraded Third Harmonic Bio from Outperform to Mkt Perform

      2/11/25 11:05:35 AM ET
      $THRD
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $THRD
    Leadership Updates

    Live Leadership Updates

    See more
    • Third Harmonic Bio Appoints Geoff McDonough, M.D., to its Board of Directors

      SAN FRANCISCO, March 28, 2024 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (NASDAQ:THRD), a biopharmaceutical company focused on advancing the next wave of medicine for inflammatory diseases, today announced the appointment of Geoff McDonough, M.D., to its Board of Directors. "Geoff is an outstanding addition to our board, bringing broad operational leadership and a depth of clinical and commercial experience that will benefit our work greatly as we advance our lead product candidate, THB335, into clinical trials for chronic spontaneous urticaria," said Natalie Holles, Chief Executive Officer of Third Harmonic Bio. "Beyond his expertise, Geoff is an excellent cultural fit with our organ

      3/28/24 8:30:00 AM ET
      $THRD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Third Harmonic Bio Appoints Christopher Murphy as Chief Financial and Business Officer and Provides Business Update

      Chris brings extensive enterprise-level leadership experience in business development, commercial operations, and corporate strategy IND-enabling toxicology studies of THB335 nearing completion; Pre-IND interaction with the U.S. FDA now complete Program remains on track to file a U.S. IND and initiate a Phase 1 study of THB335 during the first half of 2024 SAN FRANCISCO, Jan. 04, 2024 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (NASDAQ:THRD), a biopharmaceutical company focused on advancing the next wave of medicine for inflammatory diseases, today announced the appointment of Christopher Murphy as Chief Financial and Business Officer. Chris brings extensive experience in business de

      1/4/24 8:00:00 AM ET
      $THRD
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $THRD
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Third Harmonic Bio Announces Plan of Liquidation and Dissolution

      Board of Directors has approved plan to liquidate and intends to seek stockholder approval for dissolution of the Company at the Annual Meeting of Stockholders on June 5, 2025 Initial distribution expected in the range between approximately $246.6 million and $255.4 million, or approximately $5.13 and $5.33 per share of common stock, expected in the third quarter of 2025 Sale of the Company's assets, including THB335, to be initiated pending stockholder approval of the Plan of Liquidation and Dissolution SAN FRANCISCO, April 14, 2025 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (NASDAQ:THRD) today announced that the Company's board of directors, after considering opportunities to

      4/14/25 6:45:00 AM ET
      $THRD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Third Harmonic Bio Announces Fourth Quarter and Full Year 2024 Financial Results

      Recently presented THB335 Phase 1 data support advancement into Phase 2 clinical trial in chronic spontaneous urticaria (CSU) Strategic alternatives process underway to maximize value creation across all assets in the company Strong financial position with cash and cash equivalents totaling $285.1 million as of December 31, 2024 SAN FRANCISCO, March 27, 2025 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (NASDAQ:THRD), a biopharmaceutical company focused on advancing the next wave of medicine for inflammatory diseases, today reported financial results for the fourth quarter and full year ended December 31, 2024. THB335 Phase 1 Clinical Results In February 2025, the Company reported resu

      3/27/25 8:10:00 AM ET
      $THRD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Third Harmonic Bio Announces Phase 1 Clinical Results for THB335 and Provides Corporate Strategic Update

      THB335 Phase 1 data support advancement into Phase 2 clinical trial in chronic spontaneous urticaria (CSU) Company initiating process to leverage balance sheet strength to maximize shareholder value Cash and cash equivalents of approximately $285 million as of December 31, 2024 (unaudited) Management to hold conference call/webcast today Tuesday, February 11, 2025, at 8:00 a.m. EST to discuss clinical results and corporate next steps SAN FRANCISCO, Feb. 11, 2025 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (NASDAQ:THRD), a clinical-stage biopharmaceutical company focused on advancing the next wave of medicine for dermal, respiratory, and gastrointestinal inflammatory diseases, today

      2/11/25 7:00:00 AM ET
      $THRD
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $THRD
    SEC Filings

    See more
    • SEC Form SCHEDULE 13G filed by Third Harmonic Bio Inc.

      SCHEDULE 13G - Third Harmonic Bio, Inc. (0001923840) (Subject)

      5/15/25 4:37:50 PM ET
      $THRD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Third Harmonic Bio Inc.

      SCHEDULE 13G/A - Third Harmonic Bio, Inc. (0001923840) (Subject)

      5/15/25 2:28:43 PM ET
      $THRD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Third Harmonic Bio Inc.

      SCHEDULE 13G/A - Third Harmonic Bio, Inc. (0001923840) (Subject)

      5/12/25 10:43:30 AM ET
      $THRD
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $THRD
    Financials

    Live finance-specific insights

    See more
    • Third Harmonic Bio Announces Phase 1 Clinical Results for THB335 and Provides Corporate Strategic Update

      THB335 Phase 1 data support advancement into Phase 2 clinical trial in chronic spontaneous urticaria (CSU) Company initiating process to leverage balance sheet strength to maximize shareholder value Cash and cash equivalents of approximately $285 million as of December 31, 2024 (unaudited) Management to hold conference call/webcast today Tuesday, February 11, 2025, at 8:00 a.m. EST to discuss clinical results and corporate next steps SAN FRANCISCO, Feb. 11, 2025 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (NASDAQ:THRD), a clinical-stage biopharmaceutical company focused on advancing the next wave of medicine for dermal, respiratory, and gastrointestinal inflammatory diseases, today

      2/11/25 7:00:00 AM ET
      $THRD
      Biotechnology: Pharmaceutical Preparations
      Health Care